503A refers to a section of the federal Food, Drug & Cosmetic Act that lets compounding pharmacies make custom medications for individual patients using bulk ingredients on an FDA-approved list
Oluo, Ijeoma (April 19, 2017)
Strategy for appeals: Submit complete clinical documentation Cite FDA approvals explicitly (March 2024 CV indication, December 2024 OSA for Zepbound) For CV indication: include cardiology documentation and SELECT trial citation Request peer-to-peer review before formal appeal Track deadlines carefully The compounded semaglutide question During the 2022-2024 semaglutide shortage, many patients used compounded semaglutide from telehealth platforms as an alternative to Wegovy
While some people experience a noticeable decrease in hunger right away, others may need a few weeks of consistent use to observe significant changes
Min T, Prior SL, Churm R, et al
Reach out today for a free consultation to learn more about your eligibility for Ozempic injury compensation